Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Researchers create a new robotic surgery device that aims to give surgeons “superhuman” hands, accounting for patients’ breathing and eye movements, along with their own involuntary hand tremors, while they work on retinal tissues.
Florida Atlantic University researchers Lisa A. Brennan and Marc Kantorow will determine the novel mechanisms that convert immature eye lens precursor cells into functional transparent cells.
According to a National Institutes of Health (NIH)-funded clinical study, children with a type of autoimmune arthritis and associated eye inflammation are likely to experience disease recurrence when discontinuing a biologic therapy called adalimumab.
In a follow up study, researchers found that children who wore special contact lenses to slow progression of myopia maintained the treatment benefit even after they stopped wearing the contacts as older teens.
Annual Eye on the Future Teen Video Contest inspires high school students from all backgrounds to explore science. Winners receive $2,000 and a trip to NIH.
A new report summarizes proceedings from an NEI workshop on extracellular vesicles (Evs) – cell-secreted nanoparticles that mediate cell-cell communication.
New findings from a National Eye Institute-led study add a twist on how a widely used cell death marker, annexin-V, can be interpreted in the lab and the clinic for tracking retinal cell death in eye diseases such as glaucoma.
UConn scientists led by Ephraim Trakhtenberg regrew optic nerves in mice through eye injections of fibronectin peptides (pieces of the larger protein).
Study reveals how DNA damage, a hallmark of aging, compromises the retina’s function and accelerates vision loss. Targeting specific retinal cell types could lead to treatments that slow or stop progression.